Literature DB >> 25641991

Higher order response adaptive urn designs for clinical trials with highly successful treatments.

Anastasia Ivanova1, Steven Hoberman1.   

Abstract

We consider a problem of reducing the expected number of treatment failures in trials where the probability of response to treatment is close to 1 and treatments are compared based on log odds ratio. We propose a new class of urn designs for randomization of patients in a clinical trial. The new urn designs target a number of allocation proportions including the allocation proportion that yields the same power as equal allocation but significantly less expected treatment failures. The new design is compared with the doubly adaptively biased coin design, the efficient randomized adaptive design and with equal allocation. The properties of the new class of designs are studied by embedding them into a family of continuous time stochastic processes.

Entities:  

Keywords:  Doubly adaptive biased coin design; Response adaptive design; Urn model

Year:  2015        PMID: 25641991      PMCID: PMC4309394          DOI: 10.1111/rssc.12066

Source DB:  PubMed          Journal:  J R Stat Soc Ser C Appl Stat        ISSN: 0035-9254            Impact factor:   1.864


  7 in total

1.  Optimal adaptive designs for binary response trials.

Authors:  W F Rosenberger; N Stallard; A Ivanova; C N Harper; M L Ricks
Journal:  Biometrics       Date:  2001-09       Impact factor: 2.571

2.  Fondaparinux for the treatment of superficial-vein thrombosis in the legs.

Authors:  Hervé Decousus; Paolo Prandoni; Patrick Mismetti; Rupert M Bauersachs; Zoltán Boda; Benjamin Brenner; Silvy Laporte; Lajos Matyas; Saskia Middeldorp; German Sokurenko; Alain Leizorovicz
Journal:  N Engl J Med       Date:  2010-09-23       Impact factor: 91.245

3.  Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators.

Authors:  U Tebbe; R Michels; J Adgey; J Boland; A Caspi; B Charbonnier; J Windeler; H Barth; R Groves; G R Hopkins; W Fennell; A Betriu; M Ruda; J Mlczoch
Journal:  J Am Coll Cardiol       Date:  1998-03-01       Impact factor: 24.094

4.  Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.

Authors:  Lars Wallentin; Lott Bergstrand; Mikael Dellborg; Carin Fellenius; Christopher B Granger; Bertil Lindahl; Lars Eric Lins; Tage Nilsson; Kenneth Pehrsson; Agneta Siegbahn; Eva Swahn
Journal:  Eur Heart J       Date:  2003-05       Impact factor: 29.983

5.  Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group.

Authors: 
Journal:  Eur Heart J       Date:  1985-03       Impact factor: 29.983

6.  Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study.

Authors:  M Simoons; M Krzemiñska-Pakula; A Alonso; S Goodman; A Kali; U Loos; F Gosset; V Louer; F Bigonzi
Journal:  Eur Heart J       Date:  2002-08       Impact factor: 29.983

7.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.